cheap copies of its drugs, particularly anti depressants paxil and wellbutrin, and a weak dollar had hit profits, but global sales were up 1% in 2004. the firm is confident its new drug pipeline will deliver profits despite the failure of an obesity drug. glaxo is relying on new treatments for conditions such as cancer, diabetes, depression, hiv aids and allergies to lift the pace of sales growth after several disappointing years. however, the firm discontinued development of an experimental treatment for obesity, known as '771, after disappointing clinical trial results. glaxo aims high after profit fall glaxosmithkline saw its profits fall 9% last year to 6.2bn 11.5bn , but europe's biggest drugmaker says a recovery during 2005 is on the way. the continuing success of our key products means we can now look forward to a good performance in 2005, he said.